Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add filters

Language
Document Type
Year range
1.
Journal of Nuclear Medicine ; 62:2, 2021.
Article in English | Web of Science | ID: covidwho-1567745
2.
Journal of Nuclear Medicine ; 62:2, 2021.
Article in English | Web of Science | ID: covidwho-1567325
3.
Journal of Nuclear Medicine ; 62(SUPPL 1), 2021.
Article in English | EMBASE | ID: covidwho-1312276

ABSTRACT

Objectives: The coronavirus disease 2019 (COVID-19) is a viral pandemic caused by SARS-CoV-2, a member of the Coronavirinae subfamily. Myalgia is one of the most prevalent symptoms. The aim of this study is to investigatewhether there is a change in FDG uptake of the muscles and bone marrow of patients with COVID-19 infection. Method: From august 2020 to december 2020, a total of 1260 oncological FDG PET-CT studies were performed inour center. Among 242 oncology patients whose SARS-CoV-2 PCR results were available, the data of 32 patients with concurrent SARS-CoV-2 positivity or previous disease history and the data of 36 covid negative patients were analyzed retrospectively. Patients tested positive COVID-19 were divided into 3 groups (14 days, 1 month and 3months) according to the time interval between the active period of the disease and FDG PET-CT imaging. FDGuptake in paraspinal, deltoid, psoas, gluteal muscles and also sacrum of each patient were measured separately, the SUVmax and the SUVmean values were recorded. The FDG uptake in paraspinal, deltoid, psoas, gluteal muscles and sacrum of the covid-negative patient group were measured and recorded the same way as the studygroup. Other imaging findings that may be related to COVID-19 were also noted. Mann-Whitney U-test was used toassess differences in metabolic parameters between the groups. Statistical significance was defined as p<0.05.Patients were asked about their muscle pain in the active phase of the COVID-19 and the pain rating scale used torate the intensity of the pain. Results: Sixty eight patients with a mean age of 56±15 (5-80) years were included in the study. There were 32females and 36 males. Median SUVmean and SUVmax values in the psoas muscle of 15 patients whose timeperiod between the SARS-CoV-2 PCR test positivity and FDG PET-CT imaging was less than 15 days were significantly higher than the median SUVmean and SUVmax values in the psoas muscle of covid-negative patientgroup (p: 0.04 and 0.016, respectively). Moreover, the bone marrow SUVmean and SUVmax values obtained from the sacrum were also found to be higher in this group (p: 0.036 and 0.016, respectively).In the patient group whosePET-CT imaging was performed 1 month after SARS-CoV-2 PCR test positivity, the SUVmax values obtained from the psoas muscle were significantly higher than the SUVmax values in the covid negative group (p: 0.043). There was no significant difference between the SUV parameters obtained from the muscle groups and bone marrow of patients who were tested for SARS-CoV-2 positivity or with a known history of COVID-19, and the SUV parametersobtained from covid-negative patients. Conclusion: Since the disease is new, there are many questions about thecourse of the disease and its early and late findings. Despite being a small sample, in our study, it was shown thatsome COVID-19 patients in the early stage of the disease may show increased FDG uptake in some muscle groups and also in bone marrow.

4.
Journal of Nuclear Medicine ; 62(SUPPL 1), 2021.
Article in English | EMBASE | ID: covidwho-1312007

ABSTRACT

Objectives: Our aim in this study is to evaluate non-diagnostic computed tomography (CT) images obtained for attenuation purposes and single photon emission computed tomography (SPECT) images in myocardial perfusion scintigraphy (MPS) in patients with a history of COVID-19 known. Methods: The information of 287 patients who had MPS imaging with pharmacological stress in our department between October 2020 and January 2021 were retrospectively evaluated from the hospital information system. The patients were divided into two groups according to the only ground glass density on CT and the presence of Tc-99m methoxy isobutyl isonitrile (MIBI) involvement with ground glass density. The date when the patients were diagnosed with COVID-19 was recorded. Results: Twenty-two patients had a history of COVID-19. There was an average of 74±46 (15-186) days between the diagnosis of COVID-19 and MPS. Ground glass density was observed on non-diagnostic CT in 11 patients. Ten patients had increased Tc-99m MIBI uptake consistent with ground glass areas. The median time between diagnosis and MPS was calculated as 50.5 days in patients with Tc-99m MIBI involvement in the lung and 63.5 days in patients without involvement, but according to the time interval between diagnosis and MPS, there was no significant difference between them (p> 0.05). Conclusions: Although imaging models corresponding to clinical improvement in patients diagnosed with COVID- 19 usually occur after the 2nd week of the disease, they may continue for a long time after the diagnosis, moreover, increased radiopharmaceutical uptake may accompany this. Keywords: COVID-19, MPS, MIBI .

SELECTION OF CITATIONS
SEARCH DETAIL